Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Constellation Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US
Report incorrect company information
Key People/Management at Constellation Pharmaceuticals
Jigar Raythatha
President & Chief Executive Officer
Matthias Jaffe
Chief Financial Officer
Mark A. Goldsmith
Executive Chairman
James Audia
Chief Scientific Officer
Brenda Sousa
Vice President of Human Resources
Report incorrect company information
Constellation Pharmaceuticals Office Locations
Constellation Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
215 First St
Report incorrect company information
Constellation Pharmaceuticals Financials and Metrics
Summary Metrics
Founding Date | 2008 |
Total Funding | $309.5 m |
Latest funding size | $100 m |
Time since last funding | 10 days ago |
Investors | Topspin Partners, Deerfield Management, SROne, Fidelity Management and Research Company, NS Investment, Venrock Healthcare Partners, Third Rock Ventures, OrbiMed, Hillhouse Capital, Casdin Capital, Venrock, SR One, Genentech, University of California Investment Office, Solon Mack Capital, Cormorant Asset Management, Sirona Capital, Altitude Life Science Ventures, The Column Group |
Constellation Pharmaceuticals's latest funding round in April 2018 was reported to be $100 m. In total, Constellation Pharmaceuticals has raised $309.5 m
Report incorrect company information
